Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome-Reference-Cited by-同舟云学术

Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome

Published:2021-07-27 Issue:13 Volume:62 Page:3219-3225
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Megherea Oxana¹,Janes Carmen²,Kowalski Andrew³,Baron Jessica⁴,Ahn Esther⁵,Soule Ashley⁶,Newman Matthew²

Affiliation:

1. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

2. Department of Pharmacy/Oncology Division, The Johns Hopkins Hospital, Baltimore, MD, USA

3. Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA

4. NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, USA

5. Sibley Memorial Hospital, Washington, DC, USA

6. University of Kentucky HealthCare, Lexington, KY, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1957868

Reference17 articles.

1. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

2. Acute Myeloid Leukemia

3. Acute myeloid leukemia – cancer stat facts. SEER [cited 22 Sep 2020]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html

4. National comprehensive cancer network. Acute myeloid leukemia (version 2.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

5. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects;International Journal of Molecular Sciences;2024-07-19

2. Ivosidenib;Reactions Weekly;2023-01-07